← FDA DRUG APPROVALS

FDA ANDA · ANDA218454

MIDAZOLAM IN 0.8% SODIUM CHLORIDE

Sponsor: B BRAUN MEDICAL

APPLICATION
ANDA218454
TYPE
ANDA
ORIGINAL APPROVAL
2025-05-01
LATEST ACTION
2025-05-01
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

MIDAZOLAM IN 0.8% SODIUM CHLORIDEPrescription
MIDAZOLAM 100MG/100ML (1MG/ML) · SOLUTION · INTRAVENOUS
MIDAZOLAM IN 0.8% SODIUM CHLORIDEPrescription
MIDAZOLAM 50MG/50ML (1MG/ML) · SOLUTION · INTRAVENOUS

Approval history

2025-05-01UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →